Eyepoint Pharmaceuticals Inc (EYPT NASDAQ) stock market data APIs
$17.5934
-0.74(-4.2%)
as of December 5, 2025
Try our APIs with
free plan!
Eyepoint Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Prev. Close
17.5934
Open
16.8566
High
17.6572
Low
16.479
52 wk Range
3.91-17.82
Market Cap
1 469 M
Shares Outstanding
82 787 K
Revenue
42 339 K
EPS
-0.85
Beta
1.686
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Eyepoint Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eyepoint Pharmaceuticals Inc data using free add-ons & libraries
Get Eyepoint Pharmaceuticals Inc Fundamental Data
Eyepoint Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 42 339 K
- EBITDA: -216 250 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.77
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eyepoint Pharmaceuticals Inc News
New
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – �...
EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...
This article first appeared on GuruFocus. Release Date: November 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points EyePo...
EyePoint outlines top-line Phase III DURAVYU data for wet AMD expected mid-2026 as cash runway extends into Q4 2027
Earnings Call Insights: EyePoint Pharmaceuticals (EYPT) Q3 2025 MANAGEMENT VIEW * Jay Duker, President and CEO, described the quarter as one of “tremendous progress” and highlighted “our mom...
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.54 per share a year ago. These f...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
